PLN 32.2
(1.58%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 28.07 Million PLN | 68.33% |
2022 | 16.67 Million PLN | -13.76% |
2021 | 19.34 Million PLN | -27.79% |
2020 | 26.78 Million PLN | 27.42% |
2019 | 21.02 Million PLN | 43.68% |
2018 | 14.63 Million PLN | 193.78% |
2017 | 4.98 Million PLN | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 26.96 Million PLN | 13.57% |
2024 Q1 | 23.74 Million PLN | -15.42% |
2023 Q3 | 31.71 Million PLN | 39.41% |
2023 Q2 | 22.74 Million PLN | 21.06% |
2023 FY | 28.07 Million PLN | 68.33% |
2023 Q4 | 28.07 Million PLN | -11.48% |
2023 Q1 | 18.79 Million PLN | 12.67% |
2022 Q1 | 18.35 Million PLN | -5.11% |
2022 Q4 | 16.67 Million PLN | 2.61% |
2022 FY | 16.67 Million PLN | -13.76% |
2022 Q3 | 16.25 Million PLN | 26.31% |
2022 Q2 | 12.86 Million PLN | -29.88% |
2021 Q2 | 17.92 Million PLN | -16.67% |
2021 FY | 19.34 Million PLN | -27.79% |
2021 Q1 | 21.51 Million PLN | -19.68% |
2021 Q4 | 19.34 Million PLN | 23.12% |
2021 Q3 | 15.7 Million PLN | -12.37% |
2020 FY | 26.78 Million PLN | 27.42% |
2020 Q2 | 27.51 Million PLN | 0.0% |
2020 Q4 | 26.78 Million PLN | 0.0% |
2019 FY | 21.02 Million PLN | 43.68% |
2019 Q4 | 21.02 Million PLN | 0.0% |
2018 FY | 14.63 Million PLN | 193.78% |
2017 FY | 4.98 Million PLN | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Bioceltix S.A. | 2.26 Million PLN | -1137.516% |
BIOTON S.A. | 215.86 Million PLN | 86.995% |
Mabion S.A. | 90.47 Million PLN | 68.971% |
Molecure S.A. | 11.34 Million PLN | -147.464% |
NanoGroup S.A. | 1.49 Million PLN | -1784.038% |
Pharmena S.A. | 1.9 Million PLN | -1372.928% |
Poltreg S.A. | 39.58 Million PLN | 29.072% |
Pure Biologics Spólka Akcyjna | 20.84 Million PLN | -34.68% |
Ryvu Therapeutics S.A. | 120.36 Million PLN | 76.675% |
Synthaverse S.A. | 153.26 Million PLN | 81.683% |
Urteste S.A. | 1.85 Million PLN | -1413.423% |